{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:41:51Z","timestamp":1779205311145,"version":"3.51.4"},"reference-count":18,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,9,18]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>We present the case of a man in his 50s with multiple myeloma who developed foot drop after receiving bortezomib-dexamethasone combination chemotherapy. Diagnostic evaluations, including haematological parameters, nerve conduction studies and imaging, were performed to confirm the diagnosis and assess the extent of neuropathy. He was managed conservatively with analgesics and vitamin supplements, and bortezomib was temporarily withheld. The neuropathy gradually improved, and bortezomib was successfully reintroduced without recurrence of foot drop. Bortezomib-induced foot drop is a rare complication of bortezomib-based therapy in patients with multiple myeloma. Early recognition and intervention are crucial to minimise impact on quality of life. This case report emphasises the safe reintroduction of bortezomib post-neuropathy resolution, emphasising the importance of early recognition and multidisciplinary management.<\/jats:p>","DOI":"10.1136\/bcr-2024-260909","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T14:45:19Z","timestamp":1727707519000},"page":"e260909","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Bortezomib-induced neuropathy in multiple myeloma manifesting as foot drop due to peroneal nerve palsy"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-8938","authenticated-orcid":false,"given":"Ciniraj","family":"Raveendran","sequence":"first","affiliation":[{"name":"Radiation Oncology, Government Medical College Thiruvananthapuram, Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherin","family":"Sunaisha Ashrafudeen","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Government Medical College Thiruvananthapuram, Thiruvananthapuram, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IP","family":"Yadev","sequence":"additional","affiliation":[{"name":"General Surgery, Government Medical College Thiruvananthapuram, Thiruvananthapuram, Kerala, India"},{"name":"General Surgery, Government Medical College Kollam, Kollam, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"2025082708160353000_17.9.e260909.1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-007-0695-5"},{"key":"2025082708160353000_17.9.e260909.2","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.3324\/haematol.2022.282624","article-title":"Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma","volume":"108","author":"Richardson","year":"2023","journal-title":"Haematologica"},{"key":"2025082708160353000_17.9.e260909.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.01.004"},{"key":"2025082708160353000_17.9.e260909.4","article-title":"Life-threatening motor neurotoxicity in association with bortezomib","volume":"91","author":"Gupta","year":"2006","journal-title":"Haematologica"},{"key":"2025082708160353000_17.9.e260909.5","first-page":"2813","article-title":"Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib","volume":"23","author":"Peng","year":"2015","journal-title":"Support Care Cancer"},{"key":"2025082708160353000_17.9.e260909.6","first-page":"135","article-title":"Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2025082708160353000_17.9.e260909.7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061451"},{"key":"2025082708160353000_17.9.e260909.8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/BCO.0000000000000195","article-title":"Peroneal nerve palsy","volume":"26","author":"Morris","year":"2015","journal-title":"Curr Orthop Pract"},{"key":"2025082708160353000_17.9.e260909.9","first-page":"264","article-title":"Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma","volume":"51","author":"Yukinari","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"2025082708160353000_17.9.e260909.10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/10428194.2021.1992758","article-title":"Foot drop in patients treated with bortezomib - a case series and review of the literature","volume":"63","author":"Vaxman","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2025082708160353000_17.9.e260909.11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials","volume":"38","author":"Li","year":"2020","journal-title":"Hematol Oncol"},{"key":"2025082708160353000_17.9.e260909.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70068-1"},{"key":"2025082708160353000_17.9.e260909.13","first-page":"37","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymphat Cancer"},{"key":"2025082708160353000_17.9.e260909.14","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.016"},{"key":"2025082708160353000_17.9.e260909.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"2025082708160353000_17.9.e260909.16","doi-asserted-by":"crossref","first-page":"153473542211141","DOI":"10.1177\/15347354221114142","article-title":"Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study","volume":"21","author":"Maschio","year":"2022","journal-title":"Integr Cancer Ther"},{"key":"2025082708160353000_17.9.e260909.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2550-5"},{"key":"2025082708160353000_17.9.e260909.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.09.014"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-260909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:16:07Z","timestamp":1756307767000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-260909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,30]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bcr-2024-260909"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-260909","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}